Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Annesley

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
BMJ (Clinical Research Ed.)|December 22, 1990
The last gameE Annesley
The Practitioner|July 1, 1992
Why bother with a practice formulary?P Reilly, E Annesley
Frontiers in Oncology|October 9, 2014
The Biology and Targeting of FLT3 in Pediatric LeukemiaColleen E Annesley, Patrick Brown
Therapeutic Advances in Hematology|April 2, 2015
Novel agents for the treatment of childhood acute leukemiaColleen E Annesley, Patrick Brown
Journal of Clinical Neurophysiology : Official Publication of the American Electroencephalographic Society|December 19, 2019
EEG Correlates of Delirium in Children and Young Adults With CD19-Directed CAR T Cell Treatment-Related NeurotoxicityJuliane Gust, Colleen E Annesley, Rebecca A Gardner, et al.
Clinical Pharmacology and Therapeutics|November 25, 2017
The Evolution and Future of CAR T Cells for B-Cell Acute Lymphoblastic LeukemiaColleen E Annesley, Corinne Summers, Francesco Ceppi, et al.
Oncotarget|October 22, 2014
Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibitionEdward Allan R Sison, Daniel Magoon, Li Li, et al.
Oncotarget|September 12, 2015
POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALLEdward Allan R Sison, Daniel Magoon, Li Li, et al.
Oncotarget|November 20, 2018
Knock-in of the <i>Wt1</i> R394W mutation causes MDS and cooperates with <i>Flt3/ITD</i> to drive aggressive myeloid neoplasms in miceColleen E Annesley, Cara Rabik, Amy S Duffield, et al.
Blood Advances|August 25, 2022
GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patientsJuliane Gust, Stephanie D Rawlings-Rhea, Ashley L Wilson, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
BMJ (Clinical Research Ed.)|December 22, 1990
The last gameE Annesley
The Practitioner|July 1, 1992
Why bother with a practice formulary?P Reilly, E Annesley
Frontiers in Oncology|October 9, 2014
The Biology and Targeting of FLT3 in Pediatric LeukemiaColleen E Annesley, Patrick Brown
Therapeutic Advances in Hematology|April 2, 2015
Novel agents for the treatment of childhood acute leukemiaColleen E Annesley, Patrick Brown
Journal of Clinical Neurophysiology : Official Publication of the American Electroencephalographic Society|December 19, 2019
EEG Correlates of Delirium in Children and Young Adults With CD19-Directed CAR T Cell Treatment-Related NeurotoxicityJuliane Gust, Colleen E Annesley, Rebecca A Gardner, et al.
Clinical Pharmacology and Therapeutics|November 25, 2017
The Evolution and Future of CAR T Cells for B-Cell Acute Lymphoblastic LeukemiaColleen E Annesley, Corinne Summers, Francesco Ceppi, et al.
Oncotarget|October 22, 2014
Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibitionEdward Allan R Sison, Daniel Magoon, Li Li, et al.
Oncotarget|September 12, 2015
POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALLEdward Allan R Sison, Daniel Magoon, Li Li, et al.
Oncotarget|November 20, 2018
Knock-in of the <i>Wt1</i> R394W mutation causes MDS and cooperates with <i>Flt3/ITD</i> to drive aggressive myeloid neoplasms in miceColleen E Annesley, Cara Rabik, Amy S Duffield, et al.
Blood Advances|August 25, 2022
GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patientsJuliane Gust, Stephanie D Rawlings-Rhea, Ashley L Wilson, et al.
Pageof 2